newsfilter
← Latest News
GlobeNewswire·

Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market

  • Sangamo Therapeutics common stock will transition from Nasdaq Capital Market to OTCQB Venture Market on May 5, 2026.
  • The delisting follows non-compliance with Nasdaq's minimum bid price requirement.
  • Sangamo intends to request a hearing from Nasdaq to appeal the delisting determination.
  • Trading on Nasdaq is expected to suspend at the open of trading on May 5, 2026, regardless of the appeal request.
  • The stock will trade under the existing symbol SGMO on the OTCQB Venture Market starting May 5, 2026.
  • The transition is not expected to result in material impacts to Sangamo's business or operations.
  • Sangamo is negotiating multiple potential business development transactions & assessing strategic options to raise capital.
  • The company has been advised by a global investment bank regarding its capital raising & asset maximization efforts.
  • Sangamo plans to file a Current Report on Form 8-K with the SEC to provide additional details.
  • Forward-looking statements warn of risks including lack of capital resources, potential failure to secure partnerships, & uncertainty regarding the delisting appeal.